Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol

Simple item page
dc.contributor.authorNeary, Michael T.en
dc.contributor.authorMulder, Lianne M.en
dc.contributor.authorKowalski, Piotr S.en
dc.contributor.authorMacLoughlin, Ronanen
dc.contributor.authorCrean, Abina M.en
dc.contributor.authorRyan, Katie B.en
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderHealth Research Boarden
dc.contributor.funderEuropean Research Councilen
dc.contributor.funderIrish Research Councilen
dc.date.accessioned2024-01-31T15:27:17Z
dc.date.available2024-01-31T15:27:17Z
dc.date.issued2024-11-25en
dc.description.abstractIn the past decade RNA-based therapies such as small interfering RNA (siRNA) and messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for the treatment and prevention of many conditions from viral infection to cancer. Most clinically approved RNA therapies are parenterally administered which impacts patient compliance and adds to healthcare costs. Pulmonary administration via inhalation is a non-invasive means to deliver RNA and offers an attractive alternative to injection. Nebulisation is a particularly appealing method due to the capacity to deliver large RNA doses during tidal breathing. In this review, we discuss the unique physiological barriers presented by the lung to efficient nebulised RNA delivery and approaches adopted to circumvent this problem. Additionally, the different types of nebulisers are evaluated from the perspective of their suitability for RNA delivery. Furthermore, we discuss recent preclinical studies involving nebulisation of RNA and analysis in in vitro and in vivo settings. Several studies have also demonstrated the importance of an effective delivery vector in RNA nebulisation therefore we assess the variety of lipid, polymeric and hybrid-based delivery systems utilised to date. We also consider the outlook for nebulised RNA medicinal products and the hurdles which must be overcome for successful clinical translation. In summary, nebulised RNA delivery has demonstrated promising potential for the treatment of several lung-related conditions such as asthma, COPD and cystic fibrosis, to which the mode of delivery is of crucial importance for clinical success.en
dc.description.sponsorshipHealth Research Board, Ireland (Grant number EIA-2019-006); Irish Research Council (Government of Ireland Postgraduate Scholarship, Grant number GOIPG/2021/1649)en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationNeary, M.T., Mulder, L.M., Kowalski, P.S., MacLoughlin, R., Crean, A.M. and Ryan, K.B. (2024) ‘Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol’, Journal of Controlled Release, 366, pp. 812–833. Available at: https://doi.org/10.1016/j.jconrel.2023.12.012en
dc.identifier.doihttps://doi.org/10.1016/j.jconrel.2023.12.012en
dc.identifier.endpage833en
dc.identifier.issn0168-3659en
dc.identifier.journaltitleJournal of Controlled Releaseen
dc.identifier.startpage812en
dc.identifier.urihttps://hdl.handle.net/10468/15476
dc.identifier.volume366en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.ispartofJournal of Controlled Releaseen
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2275/IE/Synthesis and Solid State Pharmaceutical Centre (SSPC)/en
dc.relation.projectinfo:eu-repo/grantAgreement///101041424//Synthetic Circular RNA therapeutics for prevention of sepsis-associated organ failure/CIRCLEen
dc.rights© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectNebulisationen
dc.subjectRNAen
dc.subjectOligonucleotidesen
dc.subjectLungen
dc.subjectPulmonary deliveryen
dc.subjectNanoparticlesen
dc.titleNebulised delivery of RNA formulations to the lungs: From aerosol to cytosolen
dc.typeArticle (peer-reviewed)en
oaire.citation.volume366en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S0168365923007964-main.pdf
Size:
4.76 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pharmacy - Journal Articles
APC Microbiome Ireland - Journal Articles
Synthesis and Solid State Pharmaceutical Centre (SSPC) - Journal Articles